Panacea Biotec Limited (PANACEABIO.NS)

INR 463.0

(1.47%)

Market Cap (In INR)

28.35 Billion

Revenue (In INR)

5.59 Billion

Net Income (In INR)

-11.73 Million

Avg. Volume

801.7 Thousand

Currency
INR
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
112.35-490.55
PE
-
EPS
-
Beta Value
0.932
ISIN
INE922B01023
CUSIP
Y6695F130
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Rajesh Jain Ph.D.
Employee Count
-
Website
https://www.panaceabiotec.com
Ipo Date
2002-07-01
Details
Panacea Biotec Limited, a biotechnology company, engages in the research and development, manufacture, and marketing of pharmaceuticals, vaccines, and biosimilars in India. It operates through Vaccines and Formulations segments. The company's product portfolio includes prescription products in various therapeutic areas, such as pain management, diabetes and cardiovascular management, oncology, renal disease management, osteoporosis management, anti-tubercular, and gastro-intestinal care; and vaccines for anthrax, dengue, Japanese encephalitis, and others. It also exports its products to over 30 countries worldwide, including the United States, Germany, the Russian Federation, Sri Lanka, the Philippines, etc. The company has a collaboration agreement with the Russian Direct Investment Fund for producing Covid-19 vaccine Sputnik-V; and the Coalition for Epidemic Preparedness Innovations and Translational Health Science and Technology Institute to develop vaccine candidates that could protect against SARS-Cov-2 variants and other Beta coronaviruses. Panacea Biotec Limited was incorporated in 1984 and is based in New Delhi, India.